<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Urol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Urol</journal-id><journal-title-group><journal-title>BMC Urology</journal-title></journal-title-group><issn pub-type="epub">1471-2490</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786547</article-id><article-id pub-id-type="publisher-id">1701</article-id><article-id pub-id-type="doi">10.1186/s12894-025-01701-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Palacios</surname><given-names>Juan Manuel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kapse</surname><given-names>Pratiksha</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cortes</surname><given-names>Vanessa</given-names></name><address><email>vanessa.2.cortes@gsk.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Averbeck</surname><given-names>Marcio Augusto</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Alba</surname><given-names>Alberto Budia</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Somvanshi</surname><given-names>Suryakant</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>da Costa Cruz</surname><given-names>Danilo Souza Lima</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Fiona</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/049nnjd96</institution-id><institution-id institution-id-type="GRID">grid.419327.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1768 1287</institution-id><institution>Global Medical Urology, </institution><institution>GSK, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tvt4d48</institution-id><institution-id institution-id-type="GRID">grid.488289.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1804 8678</institution-id><institution>Global Medical Urology, </institution><institution>GSK, </institution></institution-wrap>Mumbai, India </aff><aff id="Aff3"><label>3</label>Global Medical Infectious Diseases, GSK, Bogota, Colombia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/025vmq686</institution-id><institution-id institution-id-type="GRID">grid.412519.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2166 9094</institution-id><institution>Department of Urology, Moinhos de Vento Hospital and Department of Urology, </institution><institution>S&#x000e3;o Lucas Hospital &#x02013; PUCRS, </institution></institution-wrap>Porto Alegre, Brazil </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01ar2v535</institution-id><institution-id institution-id-type="GRID">grid.84393.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 0360 9602</institution-id><institution>Department of Urology, </institution><institution>La Fe University and Polytechnic Hospital, </institution></institution-wrap>Valencia, Spain </aff><aff id="Aff6"><label>6</label>Dev Biostats, India Stats, GSK, Bangalore, India </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0198v2949</institution-id><institution-id institution-id-type="GRID">grid.412211.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 4687 5267</institution-id><institution>Department of Urology, </institution><institution>State University of Rio de Janeiro, </institution></institution-wrap>Rio de Janeiro, Brazil </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040g76k92</institution-id><institution-id institution-id-type="GRID">grid.482783.2</institution-id><institution>Brand and Integrated Research Solutions, IQVIA, </institution></institution-wrap>London, UK </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>22</elocation-id><history><date date-type="received"><day>14</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par10">Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes. This study evaluated real-world practice among urologists treating patients receiving 5-alpha reductase inhibitors.</p></sec><sec><title>Methods</title><p id="Par11">This non-interventional, cross-sectional study collected data from urologists in Spain <italic>(N</italic>&#x02009;=&#x02009;100) and Brazil <italic>(N</italic>&#x02009;=&#x02009;100) via a self-reporting questionnaire and patient record forms. Endpoints included: frequency/methodology of prostate-specific antigen monitoring, concerns about the effect of 5-alpha reductase inhibitors on prostate-specific antigen monitoring, triggers of prostate biopsy, and concerns when switching 5-alpha reductase inhibitor formulation.</p></sec><sec><title>Results</title><p id="Par12">Over half of urologists monitored prostate-specific antigen every 6&#x000a0;months (Spain 59%, Brazil 58%). Preferred methods were the <italic>&#x0201c;doubling rule&#x0201d;</italic> (Spain 66%, Brazil 41%) and <italic>&#x0201c;increase from nadir&#x0201d;</italic> (Spain 28%, Brazil 43%). A minority of urologists monitored unadjusted values (Spain 3%, Brazil 11%) or did not monitor prostate-specific antigen (Spain 1%, Brazil 3%). Most urologists ranked the potential for 5-alpha reductase inhibitors to mask prostate cancer as their top concern (Spain 65%, Brazil 56%). The most selected trigger for prostate biopsy was <italic>&#x0201c;if doubled (adjusted) prostate-specific antigen level after 6&#x000a0;months of treatment is</italic>&#x02009;&#x0003e;&#x02009;<italic>4&#x000a0;ng/mL&#x0201d;</italic> (Spain 39%, Brazil 37%). Many urologists were moderately/very concerned about the effect on prostate-specific antigen when switching 5-alpha reductase inhibitor formulation.</p></sec><sec><title>Conclusions</title><p id="Par13">An unmet need exists for standard guidance and continuous education to support optimal monitoring and interpretation of prostate-specific antigen in patients with lower urinary tract symptoms/benign prostate enlargement treated with 5-alpha reductase inhibitors.
</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12894-025-01701-1.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>5-alpha reductase inhibitors</kwd><kwd>Benign prostatic hyperplasia</kwd><kwd>Benign prostate enlargement</kwd><kwd>Prostate-specific antigen</kwd><kwd>Real-world data</kwd></kwd-group><funding-group><award-group><funding-source><institution>This study was funded by GSK (219074).</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par23">Five-alpha reductase inhibitors (5ARIs) alone or in combination with alpha-adrenergic antagonists (&#x003b1;-blockers) are indicated to treat lower urinary tract symptoms due to benign prostate enlargement (LUTS/BPE) and reduce the risk of acute urinary retention or prostatic-related surgery [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Clinical guidelines have incorporated evidence from long-term clinical studies [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>] to recommend 5ARIs as a treatment for patients with LUTS/BPE [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>].
</p><p id="Par24">LUTS/BPE and prostate cancer may coexist, and levels of prostate-specific antigen (PSA) in blood can be used to inform the risk of LUTS/BPE disease progression and screen for prostate cancer [<xref ref-type="bibr" rid="CR12">12</xref>]. PSA testing for early detection of prostate cancer is supported by clinical guidelines [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. 5ARIs lower PSA levels by reducing the size of the glandular epithelial component of the prostate, which is responsible for PSA production [<xref ref-type="bibr" rid="CR8">8</xref>]. This effect on PSA levels has created concern that 5ARI treatment may mask the early detection of prostate cancer. It has been speculated that improper PSA monitoring and interpretation in patients receiving 5ARIs could lead to delays in prostate cancer diagnosis, which may result in advanced disease and worse clinical outcomes [<xref ref-type="bibr" rid="CR13">13</xref>]. PSA levels can also be impacted by switching to alternative 5ARIs with different formulas (e.g. switching between finasteride and dutasteride, or between branded and generic 5ARI formulations) [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par25">Given the clinical relevance of appropriately monitoring and interpreting PSA in patients with LUTS/BPE receiving 5ARIs, there is a need to understand current practices. The overall aim of this study was to evaluate real-world practice among urologists monitoring PSA levels in patients with LUTS/BPE receiving 5ARIs. In doing so, it provides crucial information to identify and address gaps between evidence-based guidelines and real-world clinical practice.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design, objectives and data collection</title><p id="Par26">This non-interventional, cross-sectional study collected data from urologists in Spain and Brazil. These countries were chosen based on the prevalence of benign prostatic hyperplasia (BPH) and annual 5ARI usage. In Spain, the prevalence of BPH was estimated to be 11.8% in men&#x02009;&#x0003e;&#x02009;40&#x000a0;years and approximately 30% in men older than 70 [<xref ref-type="bibr" rid="CR15">15</xref>]. In Brazil, the prevalence of BPH in men aged 60&#x02012;90&#x000a0;years was estimated to be 53.5% [<xref ref-type="bibr" rid="CR16">16</xref>]. Spain and Brazil have relatively high usage of 5ARI globally [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Data were collected through an online, self-reporting survey comprising a questionnaire and patient record forms (PRFs; Supplementary Methods) for specific patients in the urologist&#x02019;s care, all completed by the urologist. All questions concerned patients with LUTS/BPE treated with 5ARI monotherapy or in combination with &#x003b1;-blockers.</p><p id="Par27">The objectives of this study were to: (I) investigate the frequency and methodology of PSA monitoring in patients with LUTS/BPE receiving 5ARIs; (II) gain insights into the concerns of urologists about the effect of 5ARI treatment on PSA monitoring related to prostate cancer screening; (III) investigate how changes in PSA are interpreted when considering a biopsy for prostate cancer in patients with LUTS/BPE receiving 5ARIs; and (IV) gain insights into possible urologist concerns when switching between 5ARI formulations.</p><p id="Par28">The questionnaire comprised multiple-choice, open-ended, ranking and rating parameters developed empirically through review of LUTS/BPE literature and health questionnaires. Urologists were asked to complete a PRF for each of their two most recent patients with LUTS/BPE (aged&#x02009;&#x02265;&#x02009;50&#x000a0;years and receiving 5ARI treatment initiated by the urologist in the year prior to completing the questionnaire) to better assess the current real-world practice of managing patients with LUTS/BPE. To aid accuracy, urologists were asked to consult their charts first, then answer all questions in the PRF one patient at a time.</p><p id="Par29">Questionnaire and PRF data relevant to PSA monitoring are reported here; relevant questions are outlined in Supplementary Table&#x000a0;1. For each variable collected, a pre-defined list of categories was provided for participants to choose from. The study documents were reviewed and approved by institutional review boards, in accordance with the ethical regulations of each country.</p></sec><sec id="Sec4"><title>Sample characteristics</title><p id="Par30">Urologists were recruited from Spain and Brazil <italic>(N</italic>&#x02009;=&#x02009;100 from each country; February&#x02013;April 2023). Participants were selected at random from country-specific urologist panels, including the IQVIA (formerly the Intercontinental Medical statistics (IMS) Health and Quintiles) network. IQVIA is a provider of advanced analytics, technology solutions, and clinical research services. Participants gave their consent to be contacted for research studies.</p><p id="Par31">Eligible urologists fulfilled the following inclusion criteria: 5&#x02012;35&#x000a0;years of clinical experience,&#x02009;&#x02265;&#x02009;60% of their time in direct patient care, and having personally seen and managed&#x02009;&#x02265;&#x02009;10 patients with LUTS/BPE in the month prior to completing the questionnaire. Respondents were asked 2&#x02013;3 linked questions as quality control to address the possibility of misclassification; responses were checked to ensure the questions were answered in good faith, free-text answers were appropriate, and answers did not contradict themselves across the questionnaire. Respondents were excluded if they completed the questionnaire in less than half of the average time taken across all respondents.</p><p id="Par32">Considering the nature of this study, sample size was based on a feasibility assessment with advice from an expert on BPH with extensive experience on the prevalence of LUTS/BPE and the patient population. The Power Analysis Software was used to determine if the sample size was adequate, and it determined a margin of error of 7%. Therefore, sample size was considered adequate to support quantitative analysis in this study.</p><p id="Par33">At least 350 urologists in each country were contacted to achieve the required sample size. The study recruited&#x02009;~&#x02009;5% additional respondents to ensure a total sample size of 200 urologists and 400 PRFs were available for data analysis after exclusions.</p></sec><sec id="Sec5"><title>Questionnaire and PRFs</title><p id="Par34">Urologists were provided with a link to an online screening tool and, if eligibility criteria were met, were taken through to the online questionnaire. Both the urologists and the patients described in the PRFs remained anonymous.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par35">The analysis was primarily descriptive in nature and included a correlation analysis approach to address one of the secondary objectives. Data were analyzed separately for each country to allow for country-specific treatment patterns to be examined. Furthermore, Brazil and Spain utilize different levels of government and private healthcare sector involvement. Drawing conclusions from comparing these two countries would result in inaccurate deductions. Thus, each country was analyzed independently. Frequencies and percentages of responses for a given category were presented for categorical and ordinal variables. Descriptive statistics were provided for frequency and methodology of PSA testing, concerns around effect of 5ARIs on PSA monitoring/interpretation, biopsy triggers, and treatment switching concerns. All analyses were performed using IBM SPSS statistics, version 23.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Respondent characteristics</title><p id="Par36">Overall, 100 urologists from each country were enrolled and completed the questionnaire. Supplementary Table&#x000a0;2 provides an overview of the characteristics of urologists who participated in the study. On average (standard deviation [SD]), urologists had&#x02009;&#x0003e;&#x02009;10&#x000a0;years&#x02019; experience (Spain 16&#x000a0;years [7.8], Brazil 14&#x000a0;years [8.8]). In Spain, most urologists (87%) worked in the public setting, while in Brazil, most worked in the private setting (65%). Urologists in Spain saw an average of 149 men with LUTS/BPE per month, of whom an average of 80 (54%) were treated with 5ARIs (monotherapy or in combination with an &#x003b1;-blocker). In Brazil, the average monthly LUTS/BPE caseload was 68 patients, of whom an average of 54 (79%) were treated with 5ARIs.</p><p id="Par37">A total of 400 PRFs were collected (200 from each country). In both countries, approximately half of patients were aged 55&#x02013;64&#x000a0;years, with numerically more patients in younger age groups in Brazil versus Spain (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). In both countries, approximately half of patients were diagnosed with LUTS/BPE&#x02009;&#x0003e;&#x02009;12&#x000a0;months ago (Spain 44%, Brazil 52%). Most patients had comorbidities, such as hypertension (Spain 67%, Brazil 81%) and diabetes (Spain 46%, Brazil 49%). Sexual dysfunction was present in 27% of patients in Spain and 35% in Brazil. Based on either clinical assessment or international prostate symptom scores (IPSS), most patients captured via the PRFs had <italic>&#x0201c;moderate&#x0201d;</italic> disease severity.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographics and disease characteristics of the patients included in the PRFs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient characteristic, n (%)</th><th align="left">Spain<break/>(<italic>N</italic>&#x02009;=&#x02009;200)</th><th align="left">Brazil<break/>(<italic>N</italic>&#x02009;=&#x02009;200)</th></tr></thead><tbody><tr><td align="left" colspan="3">Age, years</td></tr><tr><td align="left">&#x02003;50&#x02013;54</td><td align="left">9 (5)</td><td align="left">20 (10)</td></tr><tr><td align="left">&#x02003;55&#x02013;59</td><td align="left">41 (21)</td><td align="left">42 (21)</td></tr><tr><td align="left">&#x02003;60&#x02013;64</td><td align="left">51 (26)</td><td align="left">51 (26)</td></tr><tr><td align="left">&#x02003;65&#x02013;69</td><td align="left">28 (14)</td><td align="left">35 (18)</td></tr><tr><td align="left">&#x02003;70&#x02013;74</td><td align="left">41 (21)</td><td align="left">30 (15)</td></tr><tr><td align="left">&#x02003;75&#x02013;79</td><td align="left">19 (10)</td><td align="left">12 (6)</td></tr><tr><td align="left">&#x02003;&#x02265;&#x02009;80</td><td align="left">11 (6)</td><td align="left">10 (5)</td></tr><tr><td align="left" colspan="3">Time since diagnosis</td></tr><tr><td align="left">&#x02003;&#x0003c;&#x02009;7&#x000a0;months</td><td align="left">55 (28)</td><td align="left">52 (26)</td></tr><tr><td align="left">&#x02003;7&#x02013;12&#x000a0;months</td><td align="left">58 (29)</td><td align="left">45 (23)</td></tr><tr><td align="left">&#x02003;&#x0003e;&#x02009;12&#x000a0;months</td><td align="left">87 (44)</td><td align="left">103 (52)</td></tr><tr><td align="left" colspan="3">Comorbidities</td></tr><tr><td align="left">&#x02003;Hypertension</td><td align="left">133 (67)</td><td align="left">162 (81)</td></tr><tr><td align="left">&#x02003;Diabetes</td><td align="left">92 (46)</td><td align="left">98 (49)</td></tr><tr><td align="left">&#x02003;Dyslipidemia</td><td align="left">91 (46)</td><td align="left">65 (33)</td></tr><tr><td align="left">&#x02003;Overweight/obesity</td><td align="left">73 (37)</td><td align="left">78 (39)</td></tr><tr><td align="left">&#x02003;Cardiovascular disease</td><td align="left">55 (28)</td><td align="left">40 (20)</td></tr><tr><td align="left">&#x02003;Sexual dysfunction</td><td align="left">53 (27)</td><td align="left">69 (35)</td></tr><tr><td align="left">&#x02003;Non-prostatic malignancy</td><td align="left">4 (2)</td><td align="left">1 (0.5)</td></tr><tr><td align="left">&#x02003;Neurological condition</td><td align="left">4 (2)</td><td align="left">0 (0)</td></tr><tr><td align="left">&#x02003;No comorbidities</td><td align="left">18 (9)</td><td align="left">17 (9)</td></tr><tr><td align="left">Type of sexual dysfunction</td><td align="left"><italic>N</italic>&#x02009;=&#x02009;53</td><td align="left"><italic>N</italic>&#x02009;=&#x02009;69</td></tr><tr><td align="left">&#x02003;Erectile dysfunction</td><td align="left">46 (87)</td><td align="left">63 (91)</td></tr><tr><td align="left">&#x02003;Ejaculatory dysfunction</td><td align="left">5 (9)</td><td align="left">8 (12)</td></tr><tr><td align="left">&#x02003;Negative impact on libido/sexual desire</td><td align="left">4 (8)</td><td align="left">16 (23)</td></tr><tr><td align="left">&#x02003;Negative impact on global sexual function</td><td align="left">5 (9)</td><td align="left">10 (15)</td></tr><tr><td align="left">Risk categorization when 5ARI was initiated</td><td align="left"><italic>N</italic>&#x02009;=&#x02009;200</td><td align="left"><italic>N</italic>&#x02009;=&#x02009;200</td></tr><tr><td align="left">&#x02003;At risk of progression</td><td align="left">163 (82)</td><td align="left">176 (88)</td></tr><tr><td align="left">&#x02003;Not at risk of progression</td><td align="left">37 (19)</td><td align="left">24 (12)</td></tr><tr><td align="left">Symptom severity based on IPSS</td><td align="left"><italic>N</italic>&#x02009;=&#x02009;116</td><td align="left"><italic>N</italic>&#x02009;=&#x02009;51</td></tr><tr><td align="left">&#x02003;Severe</td><td align="left">45 (39)</td><td align="left">13 (26)</td></tr><tr><td align="left">&#x02003;Moderate</td><td align="left">68 (59)</td><td align="left">35 (69)</td></tr><tr><td align="left">&#x02003;Mild</td><td align="left">3 (3)</td><td align="left">3 (6)</td></tr><tr><td align="left">Symptom severity per clinical assessment</td><td align="left"><italic>N</italic>&#x02009;=&#x02009;81</td><td align="left"><italic>N</italic>&#x02009;=&#x02009;145</td></tr><tr><td align="left">&#x02003;Severe</td><td align="left">30 (37)</td><td align="left">41 (28)</td></tr><tr><td align="left">&#x02003;Moderate</td><td align="left">49 (61)</td><td align="left">94 (65)</td></tr><tr><td align="left">&#x02003;Mild</td><td align="left">2 (3)</td><td align="left">10 (7)</td></tr></tbody></table><table-wrap-foot><p>Percentages may not total 100% for each characteristic due to rounding. Each country was analyzed independently in this study</p><p><italic>5ARI</italic> 5-alpha reductase inhibitor, <italic>IPSS</italic> international prostate symptom score, <italic>PRF</italic>&#x000a0;patient record form</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Frequency and methodology of PSA monitoring</title><p id="Par38">Over half of urologists reported monitoring PSA levels every 6&#x000a0;months (Spain 59%, Brazil 58%). One-third of urologists reported monitoring PSA levels every 12&#x000a0;months or less (Spain 30%, Brazil 34%). A small number of urologists (5% in both countries) reported monitoring PSA levels every 3&#x000a0;months, or not monitoring PSA regularly but on a need basis only (Spain 6%, Brazil 3%).</p><p id="Par39">When asked about their method of interpreting PSA levels, 66% of urologists in Spain chose <italic>&#x0201c;using the doubling rule&#x0201d;</italic>, 28% chose <italic>&#x0201c;evaluating any increase from nadir value&#x0201d;</italic>, 3% chose <italic>&#x0201c;monitoring absolute (unadjusted) values&#x0201d;</italic>, and 1% chose <italic>&#x0201c;I do not monitor PSA levels&#x0201d;.</italic> In the PRFs, the respective percentages for these options were 54%, 26%, 15%, and 4%. In Brazil, 41% selected <italic>&#x0201c;using the doubling rule&#x0201d;</italic>, 43% of urologists selected <italic>&#x0201c;evaluating any increase from nadir value&#x0201d;</italic>, 11% selected <italic>&#x0201c;monitoring absolute (unadjusted) values&#x0201d;</italic>, and 3% selected <italic>&#x0201c;I do not monitor PSA levels&#x0201d;.</italic> In the PRFs, the respective percentages were 67%, 17%, 14%, and 1% (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Method of PSA monitoring in patients with LUTS/BPE treated with 5ARIs. Results according to (<bold>A</bold>) the questionnaire and (<bold>B</bold>) PRFs.&#x000a0;5ARI, 5-alpha reductase inhibitor; LUTS/BPE, lower urinary tract symptoms/benign prostate enlargement; PRF, patient record form; PSA, prostate-specific antigen. Each country was analyzed independently in this study</p></caption><graphic xlink:href="12894_2025_1701_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec10"><title>Urologist concerns about the effect of 5ARI treatment on PSA monitoring</title><p id="Par40">Participants were asked to indicate which of the following concerns that urologists might have when monitoring PSA in patients receiving 5ARIs were most important. The most frequently top-ranked response was <italic>&#x0201c;concerned about the effect of 5ARIs on PSA levels that may mask prostate cancer&#x0201d;</italic> (Spain 65%, Brazil 56%). The next most frequently top-ranked response was <italic>&#x0201c;concerned about how to interpret and monitor PSA in men receiving 5ARIs for prostate cancer screening&#x0201d;</italic> (Spain 18%, Brazil 39%). <italic>&#x0201c;Concerned about impact on PSA when changing between 5ARI brands and branded versus generic&#x0201d;</italic> was ranked as the highest concern by 14% of urologists in Spain and 3% in Brazil.</p></sec><sec id="Sec11"><title>Triggers for prostate biopsy</title><p id="Par41">The most selected trigger for prostate biopsy in both countries was <italic>&#x0201c;if doubled (adjusted) PSA level after 6&#x000a0;months of treatment is</italic>&#x02009;&#x0003e;&#x02009;<italic>4&#x000a0;ng/mL&#x0201d;</italic> (Spain 39%, Brazil 37%; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The next most common response from urologists in Spain was <italic>&#x0201c;any confirmed increase from nadir level&#x0201d;</italic> (20%) and in Brazil was <italic>&#x0201c;if doubled (adjusted) PSA level after 12&#x000a0;months of treatment is</italic>&#x02009;&#x0003e;&#x02009;<italic>4&#x000a0;ng/mL&#x0201d;</italic> (16%). Among those who selected <italic>&#x0201c;PSA velocity&#x0201d;</italic> (the rate of change of PSA), the range of thresholds specified by the urologists was typically between 0.7&#x02013;1&#x000a0;ng/mL/year.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Triggers for prostate biopsy in patients with LUTS/BPE treated with 5ARIs.&#x000a0;*A free-text box was provided so participants could give other triggers for prostate biopsy not included in the question. 5ARI, 5-alpha reductase inhibitor; LUTS/BPE, lower urinary tract symptoms/benign prostate enlargement; PSA, prostate-specific antigen. Each country was analyzed independently in this study</p></caption><graphic xlink:href="12894_2025_1701_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>Urologist concerns when switching 5ARI formulation</title><p id="Par42">Over half of urologists in Spain (52%) reported they were <italic>&#x0201c;moderately concerned&#x0201d;</italic> about the impact on PSA levels when changing between 5ARI molecules (dutasteride to finasteride or vice versa). Conversely, most urologists in Brazil (59%) selected the option <italic>&#x0201c;not at all concerned&#x0201d;</italic>. Fewer than one in 10 urologists in both countries were <italic>&#x0201c;very concerned&#x0201d;</italic> about the impact of switching 5ARI molecules on PSA levels (Spain 7%, Brazil 6%; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Key concerns that urologists have regarding the impact on PSA levels when changing medications. Changing from (<bold>A</bold>) dutasteride to finasteride or vice versa (<bold>B</bold>) branded to generic medications, and (<bold>C</bold>) changing between generic options of 5ARIs.&#x000a0;5ARI, 5-alpha reductase inhibitor; PSA, prostate-specific antigen. Each country was analyzed independently in this study</p></caption><graphic xlink:href="12894_2025_1701_Fig3_HTML" id="MO3"/></fig></p><p id="Par43">On changing from branded to generic 5ARIs, 51%, 29%, and 20% of urologists in Spain reported being <italic>&#x0201c;not at all concerned&#x0201d;</italic>, <italic>&#x0201c;moderately concerned&#x0201d;</italic>, and <italic>&#x0201c;very concerned&#x0201d;</italic>, respectively, about the impact on PSA levels (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). Responses from urologists in Brazil showed 35%, 52%, and 13% reporting <italic>&#x0201c;not at all concerned&#x0201d;</italic>, <italic>&#x0201c;moderately concerned&#x0201d;</italic>, and <italic>&#x0201c;very concerned&#x0201d;</italic>, respectively.</p><p id="Par44">Regarding the impact on PSA management of changing between generic medications, 59% of urologists in Spain and 47% in Brazil reported they were <italic>&#x0201c;not at all concerned&#x0201d;</italic>, 28% in Spain and 48% in Brazil answered <italic>&#x0201c;moderately concerned&#x0201d;</italic>, and 13% in Spain and 5% in Brazil selected <italic>&#x0201c;very concerned&#x0201d;</italic> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C).</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par45">Treatment with 5ARIs in patients with LUTS/BPE lowers PSA levels by approximately 50% after 6&#x000a0;months of treatment, even when prostate cancer is present [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. This has led to the concern that 5ARI treatment may mask early prostate cancer detection [<xref ref-type="bibr" rid="CR13">13</xref>]. This is reflected in our study, where over half of the urologists surveyed reported concerns about the potential masking effect of 5ARIs on prostate cancer. Most urologists considered regular PSA monitoring important in men with LUTS/BPE treated with 5ARIs, primarily for the purpose of identifying prostate cancer, and around 95% of urologists reported monitoring PSA at regular intervals.</p><p id="Par46">The effect of 5ARIs on PSA levels has led to changes in monitoring and interpreting PSA for prostate cancer detection. Currently, there are two main methods to do so in men receiving 5ARIs: the <italic>&#x0201c;doubling rule&#x0201d;</italic> and <italic>&#x0201c;increase from nadir&#x0201d;</italic>. The <italic>&#x0201c;doubling rule&#x0201d;</italic> is a method of adjusting PSA levels to account for the impact of 5ARIs; after 6&#x000a0;months of treatment with 5ARIs, PSA values are doubled and then compared with normal ranges from untreated patients [<xref ref-type="bibr" rid="CR22">22</xref>]. The second method involves establishing each patient&#x02019;s lowest PSA level (nadir) over the course of 6&#x000a0;months of treatment with 5ARIs, then monitoring for any confirmed increase from that baseline as a potential indicator of prostate cancer [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. In the REDUCE study, the <italic>&#x0201c;increase from nadir&#x0201d;</italic> method was shown to maintain the sensitivity of PSA levels as a cancer biomarker in men receiving dutasteride [<xref ref-type="bibr" rid="CR3">3</xref>]. In a prospective, multicenter study of 203 men with BPH receiving dutasteride in Japan, a&#x02009;&#x0003e;&#x02009;10% increase in PSA levels after 1&#x000a0;year of treatment significantly predicted the risk of a prostate cancer diagnosis [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par47">This study showed that both <italic>&#x0201c;increase from nadir&#x0201d;</italic> and the <italic>&#x0201c;doubling rule&#x0201d;</italic> are being used widely in real-world clinical practice; the <italic>&#x0201c;doubling rule&#x0201d;</italic> was more common, despite being considered less reliable [<xref ref-type="bibr" rid="CR25">25</xref>]. Notably, according to the PRFs, 15% of urologists in Spain and 14% in Brazil monitor absolute, unadjusted PSA values and 4% of urologists in Spain and 1% in Brazil do not monitor PSA levels at all, which is concerning. It is unsurprising that uptake of <italic>&#x0201c;increase from nadir&#x0201d;</italic> method has been limited given the inconsistencies in 5ARI labeling information and guidelines. While the European Union (EU) Summary of Product Characteristics (SmPC) for dutasteride has been updated to recommend using the <italic>&#x0201c;increase from nadir&#x0201d;</italic> method [<xref ref-type="bibr" rid="CR4">4</xref>], the SmPC for finasteride still recommends the <italic>&#x0201c;doubling rule&#x0201d;</italic> [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], whilst the Food and Drug Administration (FDA) labels for dutasteride [<xref ref-type="bibr" rid="CR27">27</xref>] and finasteride [<xref ref-type="bibr" rid="CR26">26</xref>] include instructions for both PSA monitoring methods. Furthermore, there is a lack of consensus and clarity around the most appropriate method to use in the published guidelines [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. There is an ongoing need to inform urologists of current best practices and the favorable sensitivity of the <italic>&#x0201c;increase from nadir&#x0201d;</italic> method when evaluating PSA levels in patients treated with 5ARIs.</p><p id="Par48">The PSA threshold that most urologists used to trigger a prostate biopsy was consistent between countries. Around four in 10 urologists (Spain 39%, Brazil 37%) reported the trigger to be <italic>&#x0201c;if doubled (adjusted) PSA level after 6&#x000a0;months of treatment is</italic>&#x02009;&#x0003e;&#x02009;<italic>4&#x000a0;ng/mL&#x0201d;</italic>. However, the second most chosen option differed between countries: 20% of urologists in Spain chose <italic>&#x0201c;any confirmed increase from nadir level&#x0201d;</italic>, while in Brazil, 16% selected <italic>&#x0201c;if doubled (adjusted) PSA level after 12&#x000a0;months of treatment is</italic>&#x02009;&#x0003e;&#x02009;<italic>4&#x000a0;ng/mL&#x0201d;</italic>. In the general population, a PSA level of 4&#x000a0;ng/mL is commonly used by urologists and in primary care settings, since this threshold was used in the Prostate Cancer Prevention Trial and REDUCE trial [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]; however, the optimal threshold for biopsy in clinical practice is debatable and should take other clinical factors into consideration.</p><p id="Par49">Switching between 5ARIs can substantially affect PSA levels, potentially impacting whether a biopsy is undertaken [<xref ref-type="bibr" rid="CR14">14</xref>]; this puts additional burden on urologists as they optimize treatment while considering fluctuating PSA results and their impact on prostate cancer diagnosis. This study highlights that a higher proportion of urologists in Brazil were moderately concerned about switching from branded to generic medications (52%) or from generic to branded medications (48%) versus Spain (29% and 28%, respectively). However, a higher proportion of urologists in Spain were moderately concerned when changing patients from dutasteride to finasteride or vice versa (52%) compared with Brazil (35%). More evidence is needed to understand the effects of switching 5ARIs on PSA levels and to determine how urologists should account for this to interpret any shifts that may indicate that a biopsy is required.</p><p id="Par50">The impact of treatment with 5ARIs on prostate cancer diagnosis is complex. Although some database analyses have suggested that the use of 5ARIs can lead to delayed diagnosis and worse cancer-specific mortality [<xref ref-type="bibr" rid="CR13">13</xref>], it is likely that these negative outcomes resulted from use of unadjusted PSA levels, potentially leading to incorrect PSA interpretation. More recent studies show no association between treatment with 5ARIs and increased prostate cancer mortality in men without a previous prostate cancer diagnosis [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par51">A strength of this study is the use of real-world data representative of real-world clinical practice, suggesting that the learnings from this study can be generalized to a wider population. A limitation of this study is that data were self-reported by urologists and may be prone to recall bias; however, the combined questionnaire and PRF approach may have reduced the self-reporting bias. Another limitation was the potential for selection bias, as urologist inclusion was dependent on internet availability and meeting the inclusion criteria. Additionally, data were only collected from two countries with high rates of LUTS/BPE; therefore, the results may not be representative from an international perspective. These results do, however, help identify the real-world practice of urologists in two countries where 5ARI use is high, which could help inform 5ARI prescribing, and PSA monitoring practices in countries where 5ARI use is less common. Future studies should aim to understand how clinicians use PSA density to interpret PSA levels and inform prescribing.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par52">This analysis revealed that a large proportion of urologists in Spain and Brazil have not adopted the best practice <italic>&#x0201c;increase from nadir&#x0201d;</italic> method for PSA monitoring and interpretation, and some urologists monitor unadjusted PSA values or do not monitor PSA levels at all; thus, educational efforts should continue to emphasize the appropriate method of PSA monitoring and interpretation. Urologists were concerned about the effect of 5ARIs on masking prostate cancer when monitoring PSA levels, highlighting a need to provide additional data and education on the latest evidence, which would allow urologists to make informed choices when treating and monitoring patients with LUTS/BPE receiving 5ARIs [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]. Future studies should consider the role of PSA density in patients with LUTS/BPE receiving 5ARIs.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12894_2025_1701_MOESM1_ESM.docx"><caption><p>Supplementary Material 1:&#x000a0;Supplementary Methods. Supplementary Table 1. Questions used in questionnaire and PRFs to address the study objectives. Supplementary Table 2. Characteristics of urologists who completed the questionnaire.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>5ARI</term><def><p id="Par14">5-alpha reductase inhibitor</p></def></def-item><def-item><term>BPH</term><def><p id="Par15">Benign prostatic hyperplasia</p></def></def-item><def-item><term>EU</term><def><p id="Par16">European Union</p></def></def-item><def-item><term>FDA</term><def><p id="Par17">Food and Drug Administration</p></def></def-item><def-item><term>IPSS</term><def><p id="Par18">International prostate symptom score</p></def></def-item><def-item><term>LUTS/BPE</term><def><p id="Par19">Lower urinary tract symptoms/benign prostate enlargement</p></def></def-item><def-item><term>PRF</term><def><p id="Par20">Patient record form</p></def></def-item><def-item><term>PSA</term><def><p id="Par21">Prostate-specific antigen</p></def></def-item><def-item><term>SD</term><def><p id="Par22">Standard deviation
</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Anna King, PhD, and Ciara Mulhern, BSc, of Ashfield MedComms, an Inizio company, and funded by GSK.</p><sec id="FPar1"><title>Clinical trial number</title><p id="Par53">Not applicable.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Data acquisition was performed by FP, JMP, VC, and PK, and FP, JMP, VC, PK, and SS analysed data. MAA, ABA, DSLdCC, FP, JMP, VC and SS were involved in the study design. All authors interpreted data, reviewed and approved the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by GSK (219074). The funder had a role in the conceptualization, design, data collection, analysis, decision to publish and preparation of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par54">A central independent review board (Pearl Independent Institution Review Board) considered that the research had no risk or minimal risk to participants and was exempt from most of the requirements of the Federal Policy for the Protection of Human Subjects. Written informed consent was obtained from all participants. This study was conducted according to the ethical principles outlined in the Declaration of Helsinki.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par55">This study complied with all applicable laws in the relevant countries regarding participant privacy. Urologists completed consent forms before study participation. All patient data were de-identified so informed consent was not required.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par56">JMP, PK, VC and SS are employed by and hold financial equities in GSK. MAA, ABA, DSLdCC and FP declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Aurobindo Pharma - Milpharm Ltd. Summary of product characterisics: dutasteride/tamsulosin hydrochloride 0.5 mg/0.4 mg capsules, hard. 2024. <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/11304/smpc#gref">https://www.medicines.org.uk/emc/product/11304/smpc#gref</ext-link>. Accessed 28 May 2024.
</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Aurobindo Pharma - Milpharm Ltd. Summary of product characteristics: finasteride 5mg tablets. 2024. <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/547/smpc#gref">https://www.medicines.org.uk/emc/product/547/smpc#gref</ext-link>. Accessed 13 Nov 2023.
</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Marberger</surname><given-names>M</given-names></name><name><surname>Freedland</surname><given-names>SJ</given-names></name><name><surname>Andriole</surname><given-names>GL</given-names></name><name><surname>Emberton</surname><given-names>M</given-names></name><name><surname>Pettaway</surname><given-names>C</given-names></name><name><surname>Montorsi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study</article-title><source>BJU Int</source><year>2012</year><volume>109</volume><fpage>1162</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2011.10373.x</pub-id><pub-id pub-id-type="pmid">21699645</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2012;109:1162&#x02013;9.<pub-id pub-id-type="pmid">21699645</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Rivopharm Uk Ltd. Summary of product characteristics: dutasteride 0.5mg capsules, soft. 2024. <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/8988/smpc#gref">https://www.medicines.org.uk/emc/product/8988/smpc#gref</ext-link>. Accessed 13 Nov 2023.</mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Mcconnell</surname><given-names>JD</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Bautista</surname><given-names>OM</given-names></name><name><surname>Andriole</surname><given-names>GL</given-names><suffix>Jr</suffix></name><name><surname>Dixon</surname><given-names>CM</given-names></name><name><surname>Kusek</surname><given-names>JW</given-names></name><etal/></person-group><article-title>The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>2387</fpage><lpage>2398</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030656</pub-id><pub-id pub-id-type="pmid">14681504</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Mcconnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387&#x02013;98.<pub-id pub-id-type="pmid">14681504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Siami</surname><given-names>P</given-names></name><name><surname>Barkin</surname><given-names>J</given-names></name><name><surname>Dami&#x000e3;o</surname><given-names>R</given-names></name><name><surname>Major-Walker</surname><given-names>K</given-names></name><name><surname>Morrill</surname><given-names>B</given-names></name><etal/></person-group><article-title>The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study</article-title><source>J Urol</source><year>2008</year><volume>179</volume><fpage>616</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2007.09.084</pub-id><pub-id pub-id-type="pmid">18082216</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Roehrborn CG, Siami P, Barkin J, Dami&#x000e3;o R, Major-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616&#x02013;21.<pub-id pub-id-type="pmid">18082216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Siami</surname><given-names>P</given-names></name><name><surname>Barkin</surname><given-names>J</given-names></name><name><surname>Dami&#x000e3;o</surname><given-names>R</given-names></name><name><surname>Major-Walker</surname><given-names>K</given-names></name><name><surname>Nandy</surname><given-names>I</given-names></name><etal/></person-group><article-title>The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study</article-title><source>Eur Urol</source><year>2010</year><volume>57</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2009.09.035</pub-id><pub-id pub-id-type="pmid">19825505</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Roehrborn CG, Siami P, Barkin J, Dami&#x000e3;o R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123&#x02013;31.<pub-id pub-id-type="pmid">19825505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Lerner</surname><given-names>LB</given-names></name><name><surname>Mcvary</surname><given-names>KT</given-names></name><name><surname>Barry</surname><given-names>MJ</given-names></name><name><surname>Bixler</surname><given-names>BR</given-names></name><name><surname>Dahm</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management</article-title><source>J Urol</source><year>2021</year><volume>206</volume><fpage>806</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1097/JU.0000000000002183</pub-id><pub-id pub-id-type="pmid">34384237</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lerner LB, Mcvary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management. J Urol. 2021;206:806&#x02013;17.<pub-id pub-id-type="pmid">34384237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Cornu JN, Gacci M, Hashim H, Herrmann TRW, Malde S, Netsch C, et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2023. <ext-link ext-link-type="uri" xlink:href="https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2023.pdf">https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2023.pdf</ext-link>. Accessed 28 May 2024.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>HB</given-names></name><name><surname>Albertsen</surname><given-names>PC</given-names></name><name><surname>Barry</surname><given-names>MJ</given-names></name><name><surname>Etzioni</surname><given-names>R</given-names></name><name><surname>Freedland</surname><given-names>SJ</given-names></name><name><surname>Greene</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Early detection of prostate cancer: AUA guideline</article-title><source>J Urol</source><year>2013</year><volume>190</volume><fpage>419</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2013.04.119</pub-id><pub-id pub-id-type="pmid">23659877</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419&#x02013;26.<pub-id pub-id-type="pmid">23659877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Mottet</surname><given-names>N</given-names></name><name><surname>Van Den Bergh</surname><given-names>RCN</given-names></name><name><surname>Briers</surname><given-names>E</given-names></name><name><surname>Van Den Broeck</surname><given-names>T</given-names></name><name><surname>Cumberbatch</surname><given-names>MG</given-names></name><name><surname>De Santis</surname><given-names>M</given-names></name><etal/></person-group><article-title>EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent</article-title><source>Eur Urol.</source><year>2021</year><volume>79</volume><fpage>243</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2020.09.042</pub-id><pub-id pub-id-type="pmid">33172724</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Mottet N, Van Den Bergh RCN, Briers E, Van Den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243&#x02013;62.<pub-id pub-id-type="pmid">33172724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>SV</given-names></name><name><surname>Vickers</surname><given-names>AJ</given-names></name></person-group><article-title>Screening for prostate cancer</article-title><source>Med Clin North Am</source><year>2020</year><volume>104</volume><fpage>1051</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/j.mcna.2020.08.007</pub-id><pub-id pub-id-type="pmid">33099450</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Carlsson SV, Vickers AJ. Screening for prostate cancer. Med Clin North Am. 2020;104:1051&#x02013;62.<pub-id pub-id-type="pmid">33099450</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>RR</given-names></name><name><surname>Parsons</surname><given-names>JK</given-names></name><name><surname>Bryant</surname><given-names>AK</given-names></name><name><surname>Ryan</surname><given-names>ST</given-names></name><name><surname>Kader</surname><given-names>AK</given-names></name><name><surname>Mckay</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Association of treatment with 5&#x003b1;-reductase inhibitors with time to diagnosis and mortality in prostate cancer</article-title><source>JAMA Intern Med</source><year>2019</year><volume>179</volume><fpage>812</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2019.0280</pub-id><pub-id pub-id-type="pmid">31058923</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, Mckay RR, et al. Association of treatment with 5&#x003b1;-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019;179:812&#x02013;9.<pub-id pub-id-type="pmid">31058923</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Helfand</surname><given-names>BT</given-names></name><name><surname>Blackwell</surname><given-names>RH</given-names></name><name><surname>Mcvary</surname><given-names>KT</given-names></name></person-group><article-title>Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity</article-title><source>J Urol</source><year>2010</year><volume>184</volume><fpage>218</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2010.03.020</pub-id><pub-id pub-id-type="pmid">20483154</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Helfand BT, Blackwell RH, Mcvary KT. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity. J Urol. 2010;184:218&#x02013;23.<pub-id pub-id-type="pmid">20483154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Chicharro-Molero</surname><given-names>JA</given-names></name><name><surname>Burgos-Rodriguez</surname><given-names>R</given-names></name><name><surname>Sanchez-Cruz</surname><given-names>JJ</given-names></name><name><surname>Del Rosal-Samaniego</surname><given-names>JM</given-names></name><name><surname>Rodero-Carcia</surname><given-names>P</given-names></name><name><surname>Rodriguez-Vallejo</surname><given-names>JM</given-names></name></person-group><article-title>Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older</article-title><source>J Urol</source><year>1998</year><volume>159</volume><fpage>878</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(01)63760-1</pub-id><pub-id pub-id-type="pmid">9474174</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Chicharro-Molero JA, Burgos-Rodriguez R, Sanchez-Cruz JJ, Del Rosal-Samaniego JM, Rodero-Carcia P, Rodriguez-Vallejo JM. Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol. 1998;159:878&#x02013;82.<pub-id pub-id-type="pmid">9474174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Tier</surname><given-names>CG</given-names></name><name><surname>Recart</surname><given-names>RH</given-names></name><name><surname>Lana</surname><given-names>LD</given-names></name><name><surname>Simon</surname><given-names>BS</given-names></name><name><surname>Garcia</surname><given-names>RP</given-names></name><name><surname>Furtado</surname><given-names>BG</given-names></name></person-group><article-title>Prevalence of prostatic changes in the elderly</article-title><source>Research, Society and Development</source><year>2020</year><volume>9</volume><fpage>e72953102</fpage><pub-id pub-id-type="doi">10.33448/rsd-v9i5.3102</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Tier CG, Recart RH, Lana LD, Simon BS, Garcia RP, Furtado BG. Prevalence of prostatic changes in the elderly. Research, Society and Development. 2020;9:e72953102.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Barkin</surname><given-names>J</given-names></name></person-group><article-title>Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm</article-title><source>Can J Urol.</source><year>2008</year><volume>15 Suppl 1</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">18700062</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Barkin J. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm. Can J Urol. 2008;15 Suppl 1:21&#x02013;30; discussion.<pub-id pub-id-type="pmid">18700062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro-P&#x000e9;rez</surname><given-names>J</given-names></name><name><surname>L&#x000f3;pez Alcina</surname><given-names>E</given-names></name><name><surname>Calabiug P&#x000e9;rez</surname><given-names>J</given-names></name><name><surname>Brotons Munt&#x000f3;</surname><given-names>F</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>A</given-names></name><name><surname>Vallejo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Changes in benign prostatic hyperplasia management in Valencia: a real-world evidence analysis</article-title><source>Actas Urol Esp (Engl Ed)</source><year>2024</year><volume>48</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.acuro.2023.11.006</pub-id><pub-id pub-id-type="pmid">38369289</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Navarro-P&#x000e9;rez J, L&#x000f3;pez Alcina E, Calabiug P&#x000e9;rez J, Brotons Munt&#x000f3; F, Mart&#x000ed;nez A, Vallejo L, et al. Changes in benign prostatic hyperplasia management in Valencia: a real-world evidence analysis. Actas Urol Esp (Engl Ed). 2024;48:461&#x02013;9.<pub-id pub-id-type="pmid">38369289</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Busato</surname><given-names>WFSJ</given-names></name></person-group><article-title>Use of 5&#x003b1;-reductase inhibitor and delay in prostate cancer diagnosis and treatment</article-title><source>Int Braz J Urol</source><year>2020</year><volume>46</volume><fpage>456</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1590/s1677-5538.ibju.2020.03.02</pub-id><pub-id pub-id-type="pmid">32167713</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Busato WFSJ. Use of 5&#x003b1;-reductase inhibitor and delay in prostate cancer diagnosis and treatment. Int Braz J Urol. 2020;46:456&#x02013;8.<pub-id pub-id-type="pmid">32167713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Andriole</surname><given-names>GL</given-names></name><name><surname>Bostwick</surname><given-names>DG</given-names></name><name><surname>Brawley</surname><given-names>OW</given-names></name><name><surname>Gomella</surname><given-names>LG</given-names></name><name><surname>Marberger</surname><given-names>M</given-names></name><name><surname>Montorsi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effect of dutasteride on the risk of prostate cancer</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>1192</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908127</pub-id><pub-id pub-id-type="pmid">20357281</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192&#x02013;202.<pub-id pub-id-type="pmid">20357281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Emberton</surname><given-names>M</given-names></name><name><surname>Cornel</surname><given-names>EB</given-names></name><name><surname>Bassi</surname><given-names>PF</given-names></name><name><surname>Fourcade</surname><given-names>RO</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>JM</given-names></name><name><surname>Castro</surname><given-names>R</given-names></name></person-group><article-title>Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management</article-title><source>Int J Clin Pract</source><year>2008</year><volume>62</volume><fpage>1076</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2008.01785.x</pub-id><pub-id pub-id-type="pmid">18479366</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Emberton M, Cornel EB, Bassi PF, Fourcade RO, G&#x000f3;mez JM, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract. 2008;62:1076&#x02013;86.<pub-id pub-id-type="pmid">18479366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rnebo</surname><given-names>L</given-names></name><name><surname>Nordstr&#x000f6;m</surname><given-names>T</given-names></name><name><surname>Discacciati</surname><given-names>A</given-names></name><name><surname>Palsdottir</surname><given-names>T</given-names></name><name><surname>Aly</surname><given-names>M</given-names></name><name><surname>Gr&#x000f6;nberg</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association of 5&#x003b1;-reductase inhibitors with prostate cancer mortality</article-title><source>JAMA Oncol</source><year>2022</year><volume>8</volume><fpage>1019</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2022.1501</pub-id><pub-id pub-id-type="pmid">35587340</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Bj&#x000f6;rnebo L, Nordstr&#x000f6;m T, Discacciati A, Palsdottir T, Aly M, Gr&#x000f6;nberg H, et al. Association of 5&#x003b1;-reductase inhibitors with prostate cancer mortality. JAMA Oncol. 2022;8:1019&#x02013;26.<pub-id pub-id-type="pmid">35587340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Andriole</surname><given-names>GL</given-names></name><name><surname>Marberger</surname><given-names>M</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name></person-group><article-title>Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride</article-title><source>J Urol</source><year>2006</year><volume>175</volume><fpage>1657</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)00984-5</pub-id><pub-id pub-id-type="pmid">16600723</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol. 2006;175:1657&#x02013;62.<pub-id pub-id-type="pmid">16600723</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Yoshimura</surname><given-names>K</given-names></name><name><surname>Terada</surname><given-names>N</given-names></name><name><surname>Tsukino</surname><given-names>H</given-names></name><name><surname>Murota</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>H</given-names></name><etal/></person-group><article-title>Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study)</article-title><source>Int J Urol</source><year>2021</year><volume>28</volume><fpage>849</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1111/iju.14590</pub-id><pub-id pub-id-type="pmid">34008275</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Inoue T, Yoshimura K, Terada N, Tsukino H, Murota T, Kinoshita H, et al. Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study). Int J Urol. 2021;28:849&#x02013;54.<pub-id pub-id-type="pmid">34008275</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>LS</given-names></name><name><surname>Andriole</surname><given-names>GL</given-names></name><name><surname>Fitzpatrick</surname><given-names>JM</given-names></name><name><surname>Schulman</surname><given-names>CC</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name></person-group><article-title>The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations</article-title><source>J Urol</source><year>2006</year><volume>176</volume><fpage>868</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2006.04.024</pub-id><pub-id pub-id-type="pmid">16890642</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006;176:868&#x02013;74.<pub-id pub-id-type="pmid">16890642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Merck &#x00026; Co. Inc. US prescribing information: PROPECIA<sup>&#x000ae;</sup> (finasteride) tablets for oral use. 2012. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf</ext-link>. Accessed 13 Nov 2023.
</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Glaxosmithkline. US prescribing information: AVODART (dutasteride) soft gelatin capsules. 2011. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021319s023s025lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021319s023s025lbl.pdf</ext-link>. Accessed 13 Nov 2023.</mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>IM</given-names></name><name><surname>Chi</surname><given-names>C</given-names></name><name><surname>Ankerst</surname><given-names>DP</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Effect of finasteride on the sensitivity of PSA for detecting prostate cancer</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><fpage>1128</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1093/jnci/djj307</pub-id><pub-id pub-id-type="pmid">16912265</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128&#x02013;33.<pub-id pub-id-type="pmid">16912265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Obinata</surname><given-names>D</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Yamanaka</surname><given-names>Y</given-names></name><name><surname>Yoshizawa</surname><given-names>T</given-names></name><name><surname>Mochida</surname><given-names>J</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: a retrospective study</article-title><source>Andrologia</source><year>2020</year><volume>52</volume><fpage>e13810</fpage><pub-id pub-id-type="doi">10.1111/and.13810</pub-id><pub-id pub-id-type="pmid">32816374</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Obinata D, Suzuki S, Yamanaka Y, Yoshizawa T, Mochida J, Yamaguchi K, et al. Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: a retrospective study. Andrologia. 2020;52:e13810.<pub-id pub-id-type="pmid">32816374</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Azoulay</surname><given-names>L</given-names></name><name><surname>Eberg</surname><given-names>M</given-names></name><name><surname>Benayoun</surname><given-names>S</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name></person-group><article-title>5&#x003b1;-reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer</article-title><source>JAMA Oncol</source><year>2015</year><volume>1</volume><fpage>314</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.0387</pub-id><pub-id pub-id-type="pmid">26181177</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Azoulay L, Eberg M, Benayoun S, Pollak M. 5&#x003b1;-reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer. JAMA Oncol. 2015;1:314&#x02013;20.<pub-id pub-id-type="pmid">26181177</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Preston</surname><given-names>MA</given-names></name><name><surname>Wilson</surname><given-names>KM</given-names></name><name><surname>Markt</surname><given-names>SC</given-names></name><name><surname>Ge</surname><given-names>R</given-names></name><name><surname>Morash</surname><given-names>C</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>5&#x003b1;-reductase inhibitors and risk of high-grade or lethal prostate cancer</article-title><source>JAMA Intern Med</source><year>2014</year><volume>174</volume><fpage>1301</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2014.1600</pub-id><pub-id pub-id-type="pmid">24887392</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, et al. 5&#x003b1;-reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014;174:1301&#x02013;7.<pub-id pub-id-type="pmid">24887392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Garmo</surname><given-names>H</given-names></name><name><surname>Bill-Axelson</surname><given-names>A</given-names></name><name><surname>Mucci</surname><given-names>L</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name><name><surname>Stattin</surname><given-names>P</given-names></name></person-group><article-title>Use of 5&#x003b1;-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study</article-title><source>BMJ</source><year>2013</year><volume>346</volume><fpage>f3406</fpage><pub-id pub-id-type="doi">10.1136/bmj.f3406</pub-id><pub-id pub-id-type="pmid">23778271</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5&#x003b1;-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013;346:f3406.<pub-id pub-id-type="pmid">23778271</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Wallerstedt</surname><given-names>A</given-names></name><name><surname>Strom</surname><given-names>P</given-names></name><name><surname>Gronberg</surname><given-names>H</given-names></name><name><surname>Nordstrom</surname><given-names>T</given-names></name><name><surname>Eklund</surname><given-names>M</given-names></name></person-group><article-title>Risk of prostate cancer in men treated with 5&#x003b1;-reductase inhibitors - a large population-based prospective study</article-title><source>J Natl Cancer Inst</source><year>2018</year><volume>110</volume><fpage>1216</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1093/jnci/djy036</pub-id><pub-id pub-id-type="pmid">29548030</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M. Risk of prostate cancer in men treated with 5&#x003b1;-reductase inhibitors - a large population-based prospective study. J Natl Cancer Inst. 2018;110:1216&#x02013;21.<pub-id pub-id-type="pmid">29548030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Wallner</surname><given-names>LP</given-names></name><name><surname>Dibello</surname><given-names>JR</given-names></name><name><surname>Li</surname><given-names>BH</given-names></name><name><surname>Van Den Eeden</surname><given-names>SK</given-names></name><name><surname>Weinmann</surname><given-names>S</given-names></name><name><surname>Ritzwoller</surname><given-names>DP</given-names></name><etal/></person-group><article-title>5-alpha reductase inhibitors and the risk of prostate cancer mortality in men treated for benign prostatic hyperplasia</article-title><source>Mayo Clin Proc</source><year>2016</year><volume>91</volume><fpage>1717</fpage><lpage>1726</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2016.07.023</pub-id><pub-id pub-id-type="pmid">28126151</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Wallner LP, Dibello JR, Li BH, Van Den Eeden SK, Weinmann S, Ritzwoller DP, et al. 5-alpha reductase inhibitors and the risk of prostate cancer mortality in men treated for benign prostatic hyperplasia. Mayo Clin Proc. 2016;91:1717&#x02013;26.<pub-id pub-id-type="pmid">28126151</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>